| Interim report January – September 2020 | Report (pdf) |
| Promore Pharma AB (publ) Interim report January – June 2020 | Report (pdf) |
| Promore Pharma AB (publ) Interim report January – March 2020 | Report (pdf) |
| Annual Report 2019 | Report (pdf) |
| Promore Pharma AB (publ) Year-end report 2019 | Report (pdf) |
The RespiraSense™ business model consists of several components that together create a complete delivery that generates attractive gross margins and recurring revenues.
To avoid preventable respiratory failure events by transforming the standard of care in patient monitoring.
To become the de facto standard-of-care for monitoring respiratory compromised patients in Europe and the US.